Chapter 55

Reference

  1. Adler-Moore JP, Proffitt RT. 1993. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar liposomal-formulation of amphotericin B. J Liposome Res 3:376-381.
  2. Andes D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 20:679-697.
  3. Andes D, Safdar N, Marchillo K, et al. 2006. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 50:674-684.
  4. Andes D, Van Ogtrop M. 2000. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 44:938-942.
  5. Angarano D, Scott D. 1987. Use of ketoconazole in treatment of dermatophytosis in a dog. J Am Vet Med Assoc 190:1433-1434.
  6. Antony SJ, Jurczyk P, Brumble L. 2006. Successful use of combination antifungal therapy in the treatment of Coccidioides meningitis. J Natl Med Assoc 98:940-942.
  7. Bariola JR, Perry P, Pappas PG, et al. 2010. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 50:797-804.
  8. Bartsch R, Greene R. 1997. New treatment of coccidioidomycosis. Vet Forum 25:50-52.
  9. Bekersky I, Boswell GW, Hiles R, et al. 1999. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 16:1694-1701.
  10. Bekersky I, Puhl RJ, Hanson G, et al. 1994. The pharmacokinetics of DMP lactate, a new agent against opportunistic infections in male beagle dogs. Drug Metab Dispos 22:233-236.
  11. Bensignor E. 2001. Comparison of two dosages of ketoconazole for treatment of Malassezia dermatitis in the dog. Ann Med Vet 145:311-316.
  12. Ben-Ziony Y, Arzi B. 2000. Use of lufenuron for treating fungal infections of dogs and cats: 297 cases (1997-1999). J Am Vet Med Assoc 217:1510-1513.
  13. Ben-Ziony Y, Arzi B. 2001. Updated information for treatment of fungal infections in cats and dogs. J Am Vet Med Assoc 218:1718.
  14. Bernard EM, Armstrong D. 1997. Treatment of opportunistic fungal infections: clinical overview and perspective. Int J Infect Dis 1(Suppl 1):528-531.
  15. Boothe DA, Herring I, Calvin J, et al. 1997. Itraconazole disposition after single oral and intravenous and multiple dosing in healthy cats. Am J Vet Res 58:872-877.
  16. Bourdeau P, Marchand AM, Etoré F. 2004. In vitro activity of posaconazole and other antifungals against Malassezia pachydermatis isolated from dogs. Vet Dermatol 15:46.
  17. Boyle JA. 2000. Controlled trials of amphotericin B lipid complex. Clin Infect Dis 31:1116-1117.
  18. Bray JP, White RAS, Lascelles BDX. 1998. Treatment of canine nasal aspergillosis with a new non-invasive technique. Failure with enilconazole. J Small Anim Pract 39:223-226.
  19. Brooks DE, Legendre AM, Gum GG, et al. 1991. The treatment of canine ocular blastomycosis with systemically administered itraconazole. Prog Vet Comp Ophthalmol 1:263-268.
  20. Callot D, Bassaris H, McGeer A, et al. 2001. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33:83-90.
  21. Casadevall A, Pirofski LA. 2001. Adjunctive immune therapy for fungal infections. Clin Infect Dis 33:1048-1056.
  22. Castanon-Olivares LR, Manzano-Gayosso P, Lopez-Martinez R, et al. 2001. Effectiveness of terbinafine in the eradication of Microsporum canis from laboratory cats. Mycoses 44:95-97.
  23. 22a. Chen SCA, Slavin MA, Sorrell TC. 2011. Echinocandin antifungal drugs in fungal infections. Drugs 71:11-41.
  24. 22b. Clemans JM, Dietz KL, Riedesel EA, et al. 2011. Retroperitoneal pyogranulomatous and fibrosing inflammation secondary to fungal infections in two dogs. J Am Vet Med Assoc 238:213-219.
  25. Clemons KV, Sobel RA, Stevens DA. 2000. Toxicity of LY 303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrob Agents Chemother 44:378-381.
  26. Cohn MS. 1992. Superficial fungal infections. Postgrad Med 91:239-252.
  27. Colombo S, Cornegliani L, Verecelli A. 2001. Efficacy of itraconazole as a combined continuous/pulse therapy in feline dermatophytosis: preliminary results in nine cases. Vet Dermatol 12:347-350.
  28. Conte L, Ramis J, Mis R, et al. 1992. Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Arzneimforsch/Drug Res 42:854-858.
  29. Craig AJ, Ramzan I, Malik R. 1994. Pharmacokinetics of fluconazole in cats after intravenous and oral administration. Res Vet Sci 57:372-376.
  30. 27a. Cuenca-Estrella M, Bassetti M, Lass-Florl C, et al. 2011. Detection and investigation of invasive mould disease. J Antimicrob Chemother 66(Suppl):15-24.
  31. Davies C, Troy GC. 1996. Deep mycotic infections in cat. J Am Anim Hosp Assoc 32:380-391.
  32. DeBoer D, Moriello K. 2002. Efficacy of pre-treatment with lufenuron for prevention of Microsporum canis infection in a feline cohabitant challenge model. Vet Dermatol 13:215.
  33. DeBoer DJ, Moriella KA. 1995. Inability of two topical treatments to influence the course of experimentally induced dermatophytosis in cats. J Am Vet Med Assoc 207:52-57.
  34. DeBoer DJ, Moriello KA, Blum JL, et al. 2003. Effects of lufenuron treatment in cats on the establishment and course of Microsporum canis infection following exposure to infected cats. J Am Vet Med Assoc 222:1216-1220.
  35. DeBoer DJ, Moriello KA, Cairns R. 1995. Clinical update on feline dermatophytosis: part II. Compend Cont Educ Pract Vet 17:1471-1480.
  36. de Jaham C, Page N, Lambert AJ, et al. 1998. Enilconazole emulsion in the treatment of dermatophytosis in Persian cats, pp 299-307. In Kwochka KW, Willemse T, Von Tsharner C (eds): Advances in veterinary dermatology, vol 3. Proceedings of the Third World Congress of Veterinary Dermatology. Butterworth-Heinemann, Oxford, UK.
  37. de Jaham C, Paradis M, Papich MG. 2000. Antifungal dermatologic agents: azoles and allylamines. Compend Cont Educ Pract Vet 22:548-566.
  38. De Keyser H, Van Den Brande M. 1983. Ketoconazole in the treatment of dermatomycosis in cats and dogs. Vet Quart 5:142-144.
  39. Deresinski SC, Stevens DA. 2003. Caspofungin. Clin Infect Dis 36:1445-1457.
  40. Dismukes WE. 2000. Introduction to antifungal drugs. Clin Infect Dis 30:653-657.
  41. Dye C, Johnson EM, Gruffydd-Jones TJ. 2009. Alternaria species infection in nine domestic cats. J Feline Med Surg 11:332-336.
  42. Espinel-Ingroff A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20:121-136.
  43. European Medicines Agency (EMEA). 2005. Posaconazole: scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000611/WC500056313.pdf. Accessed 2/5/11.
  44. European Medicines Agency (EMEA). 2009. Voriconazole: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000387/WC500049753.pdf. Accessed 2/5/11.
  45. European Medicines Agency (EMEA). 2009. Voriconazole: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000387/WC500049753.pdf. Accessed 2/5/11.
  46. Fielding RM, Singer AW, Wang LH. 1992. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 36:299-307.
  47. Fielding RM, Smith PC, Wang LH, et al. 1991. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208-1213.
  48. Fondati A, Gallo MG, Romano E, et al. 2001. A case of feline phaeohyphomycosis due to Fonsecaea pedrosoi. Vet Dermatol 12:297-301.
  49. Forward ZA, Legendre AM, Singh HD. 2002. Use of intermittent bladder infusion with clotrimazole for treatment of candiduria in a dog. J Am Vet Med Assoc 220:1496-1498.
  50. Foust AL, Marsella R, Akucewich LA, et al. 2007. Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy. Vet Dermatol 18:246-251.
  51. 47a. Foy DS, Trepanier LA. 2010. Antifungal treatment of small animal veterinary patients. Vet Clin Small Anim 40:1171-1188.
  52. 47b. Freifielde AG, Bow EJ, Sepkowitz KA, et al. 2011. Executive summary: Clinical practice guidelines for the use of antimivrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427-431.
  53. Gaboriau F, Chéron M, Petit C, Bolard J. 1997. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob Agents Chemother 41:2345-2351.
  54. Garcia ME, Guedeja-Marron J, Lazaro M, et al. 2004. Monitoring of canine dermatophytosis by an immunodiagnostic method. Vet Rec 154:116-117.
  55. Geer ND. 2007. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 20:188-196.
  56. 50a. Gorski E, Esterly JS, Postelnick M, et al. 2010. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. Antimicrob Agents Chemother 55:184-189.
  57. Goulden V, Goodfield MJD. 1995. Treatment of childhood dermatophyte infections with oral terbinafine. Pediatr Dermatol 12:53-54.
  58. Graybill JR, Stevens DA, Galgani N, et al. 1990. Itraconazole treatment of coccidioidomycosis. Am J Med 89:282-290.
  59. Greene CE. 1990. Antifungal chemotherapy, pp 649-658. In Greene CE (ed): Infectious diseases of the dog and cat, ed 1. WB Saunders, Philadelphia.
  60. Greene CE, Watson ADJ. 1998. Antifungal chemotherapy, pp 357-362. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  61. Greene RT, Troy GC. 1995. Coccidioidomycosis in 48 cats: a retrospective study (1984-1993). J Vet Intern Med 9:86-91.
  62. Groll AH, Walsh TJ. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med Weekly 132:303-311.
  63. Grooters AM, Taboada J. 2003. Update on antifungal therapy. Vet Clin North Am Small Anim Pract 33:749-758.
  64. 57a. Grundon RA, O’Reilly A, Muhlnickel C, et al. 2010. Keratomycosis in a dog treated with topical 1% voriconazole solution. Vet Ophthalmol 13:331-335.
  65. Guaguere J, Guaguere E, Bourdoiseau G. 1999. Nasal aspergillosis in the dog: surgical treatment or systemic treatment with itraconazole. Pratique Chirurgicale de L’animal de Compagnie 34:145-152.
  66. Guillot J, Bensignor E, Jankowski F, et al. 2003. Comparative efficacies of oral ketoconazole and terbinafine for reducing Malassezia population sizes on the skin of basset hounds. Vet Dermatol 14:153-157.
  67. Guillot J, Chermette R. 1997. The treatment of mycoses in carnivores. Point Veterinaire 28:51-61.
  68. Guillot J, Malandain F, Jankowski F, et al. 2002. Evaluation of the efficacy of oral lufenuron combined with topical enilconazole for the management of dermatophytosis in catteries. Vet Rec 150:714-718.
  69. Guo LS, Fielding RM, Mufson D. 1991. Pharmacokinetic study of a novel amphotericin B colloidal dispersion with improved therapeutic index. Ann NY Acad Sci 618:586-588.
  70. Haynes RR, Connolly PA, Durkin MM, et al. 2002. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis 185:1830-1832.
  71. Hector RF. 2005. An overview of antifungal drugs and their use for treatment of deep and superficial mycoses in animals. Clin Tech Small Anim Pract 20:240-249.
  72. Heit MC, Riviere JE. 1995. Antifungal therapy: ketoconazole and other azole derivatives. Compend Cont Educ Pract Vet 17:21-31.
  73. Hensel P, Greene CE, Medleau L, et al. 2003. Immunotherapy for treatment of multicentric cutaneous pythiosis in a dog. J Am Vet Med Assoc 223:197, 215-218.
  74. Herbrecht R. 1996. The changing epidemiology of fungal infections: are the lipid-based forms of amphotericin B an advance? Eur J Haematol 56:12-17.
  75. Herbrecht R, Denning DW, Patterson TF, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415.
  76. Herbrecht R, Letscher V, Kurtz JE, et al. 1997. Amphotericin B lipid complex in the management of emerging fungal pathogens. Int J Infect Dis 1(Suppl 1):542-546.
  77. Heseltine JC, Panciera DL, Saunders GK. 2003. Systemic candidiasis in a dog. J Am Vet Med Assoc 223:810, 821-824.
  78. Hnilica KA, Medleau L. 2002. Evaluation of topically applied enilconazole for the treatment of dermatophytosis in a Persian cattery. Vet Dermatol 13:23-28.
  79. Hodges RD, Legendre AM, Adams LG, et al. 1994. Itraconazole for the treatment of histoplasmosis in cats. J Vet Intern Med 8:409-413.
  80. Hofbauer B, Leitner I, Ryder NS. 2002. In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. Med Mycol 40:179-183.
  81. Jabra-Rizk MA, Falkler WA, Meiller TF. 2004. Fungal biofilms and drug resistance. Emerg Infect Dis 10:14-19.
  82. Jankegt R, deMarie S, Bakker-Woudenberg I, et al. 1992. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 23:279-291.
  83. Janoff AS, Perkins WR, Saletan SL, et al. 1993. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 3:451-471.
  84. Jensen JC. 1989. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 14:110-113.
  85. Jezequel SG. 1994. Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. J Pharm Pharmacol 46:196-199.
  86. Jin Y, Lin D. 2005. Fungal urinary tract infections in dog and cat: a retrospective study (2001-2004). J Am Anim Hosp Assoc 41: 373-381.
  87. Johnson LB, Kauffman CA. 2003. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630-637.
  88. Jones TC. 1995. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 132:683-689.
  89. Kauffman CA, Wiseman SW. 1998. Anaphylaxis upon switching lipid-containing amphotericin B formulations. Clin Infect Dis 26:1237-1238.
  90. Kaufman AC, Greene CE, Selcer BA, et al. 1994. Systemic aspergillosis in a dog and treatment with hamycin. J Am Anim Hosp Assoc 30:132-136.
  91. Kerl ME. 2003. Update on canine and feline fungal diseases. Vet Clin North Am Small Anim Pract 33:721-747.
  92. Kesson AM, Bellemore MC, O’Mara TJ, et al. 2009. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphosphocholine (miltefosine) in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 48:1257-1261.
  93. Kethireddy S, Andes D. 2007. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 3:573-581.
  94. Kim H, Likhari P, Kumari P, et al. 2000. High performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum. J Chromatogr B Biomed Sci Appl 738:93-98.
  95. Kim SH, Yong HC, Yoon JH, et al. 2003. Aspergillus niger pulmonary infection in a dog. J Vet Med Sci 65:1139-1140.
  96. King CT, Rogers PD, Cleary JD, Chapman SW. 1998. Antifungal therapy during pregnancy. Clin Infect Dis 27:1151-1160.
  97. Kontoyiannis DP. 2002. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 34:1281-1283.
  98. Kotnik T. 2002. Drug efficacy of terbinafine hydrochloride (Lamisil) during oral treatment of cats, experimentally infected with Microsporum canis. J Vet Med B Infect Dis Vet Public Health 49:120-122.
  99. Kotnik T, Kozuh Erzen N, Kuzner J, et al. 2001. Terbinafine hydrochloride treatment of Microsporum canis experimentally-induced ringworm in cats. Vet Microbiol 83:161-168.
  100. Krawiec DR, McKiernan BC, Twardock AR, et al. 1996. Use of amphotericin B lipid complex for treatment of blastomycosis in dogs. J Am Vet Med Assoc 209:2073-2075.
  101. Krishna G, Moton A, Ma L, et al. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53:958-966.
  102. Krohne SG. 2000. Canine systemic fungal infections. Vet Clin North Am Small Anim Pract 30:1063-1090.
  103. KuKanich B. 2009. A review of selected systemic antifungal drugs for use in dogs and cats. http://veterinarymedicine.dvm360.com/vetmed/Medicine/ArticleStandard/Article/detail/483478. Accessed 7/1/09.
  104. Kumar B, Kaur I, Chakrabarti A, et al. 1991. Treatment of deep mycoses with itraconazole. Mycopathologia 115:169-174.
  105. Kuroha M, Azumano A, Kuze Y, et al. 2002. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metab Dispos 30:63-68.
  106. Lanthier T, Chaliforex A. 1991. Enilconazole as an adjunct to the treatment of four cases of canine nasal aspergillosis. Can Vet J 32:110-112.
  107. Leenders AC, de Marie S. 1996. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10:1570-1575.
  108. Leisweitz AL, Rademeyer C, Picard J. 2002. The use of liposomal amphotericin B in the management of Xylohypha bantiana mycosis in a dog. J South Afr Vet Assoc 73:79-82.
  109. Leitner MI, Meingassner JG. 1994. The efficacy of orally applied terbinafine, itraconazole and fluconazole in models of experimental trichophytoses. J Med Vet Mycol 32:181-188.
  110. Levy JK. 1991. Ataxia in a kitten treated with griseofulvin. J Am Vet Med Assoc 198:105-106.
  111. Lewis RE, Prince RA, Chi J, et al. 2002. Itraconazole preexposure attenuated the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208-3214.
  112. Li RK, Rinaldi MG. 1999. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 43:401-405.
  113. 105a. Lipp HP. 2011. Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses 54:32-38.
  114. Malik R, Craig AJ, Wigney DI, et al. 1996. Combination chemotherapy of canine and feline cryptococcosis using subcutaneously administered amphotericin B. Aust Vet J 73:124-128.
  115. Malik R, Dill-Macky E, Martin P, et al. 1995. Cryptococcosis in dogs: a retrospective study of 20 consecutive cases. J Med Vet Mycol 33:291-297.
  116. 107a. Malik R. 2010. The fight against some formidable fungal foes. J Feline Med Surg 12:669-671.
  117. Malik R, Medeiros C, Wigney DI. 1996. Suspected drug eruption in 7 dogs during administration of flucytosine. Aust Vet J 74:285-288.
  118. Malik R, Wigney DI, Muir DB, et al. 1992. Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole. J Med Vet Mycol 30:133-134.
  119. Mancianati F, Pedonese F, Millanta F, et al. 1999. Efficacy of oral terbinafine in feline dermatophytosis due to Microsporum canis. J Feline Med Surg 1:37-41.
  120. Mancianati F, Pedonese F, Zullino C. 1998. Efficacy of oral administration of itraconazole to cats with dermatophytosis caused by Microsporum canis. J Am Vet Med Assoc 213:993-995.
  121. Martin S. 1999. Itraconazole. Compend Cont Educ Pract Vet 21:145-147.
  122. Mathew BP, Nath M. 2009. Recent approaches to antifungal therapy for invasive mycoses. Chem Med Chem 4:310-323.
  123. Mathews KG, Linder KE, Davidson GS, et al. 2009. Assessment of clotrimazole gels for in vitro stability and in vivo retention in the frontal sinus of dogs. Am J Vet Res 70:640-647.
  124. Mayer UK, Glos K, Schmidt M, et al. 2008. Adverse effects of ketoconazole in dogs—a retrospective study. Vet Dermatol 19:199-208.
  125. McLellan GJ, Aquino SM, Mason DR, et al. 2006. Use of posaconazole in the management of invasive orbital aspergillosis in a cat. J Am Anim Hosp Assoc 42:302-307.
  126. McCullough SM, McKiernan BC, Grodsky BS. 1998. Endoscopically placed tubes for administration of enilconazole for treatment of nasal aspergillosis in dogs. J Am Vet Med Assoc 212:67-69.
  127. Medleau L, Greene C, Rakich P. 1990. Evaluation of ketoconazole and itraconazole for treatment of disseminated cryptococcosis in cats. Am J Vet Res 51:1454-1458.
  128. Medleau L, Jacobs GJ, Marks MA. 1995. Itraconazole for the treatment of cryptococcosis in cats. J Vet Intern Med 9:39-42.
  129. Mehta RT, McQueen TJ, Keyhani A, et al. 1991. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis 164:1003-1006.
  130. Moen MD, Lysent-Williamson KA, Scott LJ. 2009. Liposomal amphotericin B. A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392.
  131. Mora-Duarte J, Betts R, Rotstein C, et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Eng J Med 347:2020-2029.
  132. Moriello KA, DeBoer DJ. 1995. Efficacy griseofulvin and itraconazole in the treatment of experimentally induced dermatophytosis in cats. J Am Vet Med Assoc 207:439-444.
  133. 123a. Naranjo TW, Lopera DE, Diaz-Granados LR, et al. 2011. Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice. Pulm Pharmacol Therap 24:81-91.
  134. Neely M, Jafri HS, Seibel N, et al. 2009. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 53:1450-1456.
  135. Nemunaitis J. 1998. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 26:1279-1281.
  136. 125a. Newbury S, Moriello KA, Kwochka KW, et al. 2010. Use of itraconazole and either lime sulphur or Malaseb Concentrate Rinse® to treat shelter catgs naturally infected with Microsporum canis: an open field trial. Vet Dermatol 22:75-79.
  137. Nichols AJ, Koster PF, Brooks DP, et al. 1992. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Ther 260:269-274.
  138. Nix DE, Swezey RS, Hector R, et al. 2009. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother 53:2517-2521.
  139. Nomeir AA, Kumari P, Hilbert MJ, et al. 2000. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 44:727-731.
  140. Okabayashi K, Imaji M, Osumi T, et al. 2009. Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses. Jpn J Med Mycol 50:91-94.
  141. Oliva G, Gradoni L, Ciaramella P, et al. 1995. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 36:1013-1019.
  142. Oppenheim BA, Herbrecht R, Kusne S. 1995. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 21:1145-1153.
  143. Ostrosky-Zeichner L, Marr KA, Rex JH, et al. 2003. Amphotericin B: time for a new "gold standard." Clin Infect Dis 37:415-423.
  144. O’Toole TE, Sato AF, Rozanski EA. 2003. Cryptococcosis in the central nervous system in a dog. J Am Vet Med Assoc 222:1722-1725.
  145. Pagano L, Gleissner B, Fianchi L. 2005. Breakthrough zygomycosis and voriconazole [letter]. J Infect Dis 192:1496-1497.
  146. Pappas PG. 2005. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the collaborative exchange of antifungal research (CLEAR) on industry supported patient registry. Clin Infect Dis 40:5379-5383.
  147. Pappas PG, Kauffman CA, Andes D, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535.
  148. Parize P, Chandesris MO, Lanternier F, et al. 2009. Antifungal therapy of Aspergillus invasive otitis externa: efficacy of voriconazole and review. Antimicrob Agents Chemother 53:1048-1053.
  149. Patricelli AJ, Hardie RJ, McAnulty JF. 2002. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 220:1009-1016.
  150. Perfect JR, Marr KA, Walsh TJ, et al. 2003. Voriconazole treatment for less-common emerging or refractory fungal infections. Clin Infect Dis 36:1122-1131.
  151. Perrins N, Howell SA, Moore M, et al. 2005. Inhibition of the growth in vitro of Trichophyton mentagrophytes, Trichophyton erinacei and Microsporum persicolor by miconazole and chlorhexidine. Vet Dermatol 16:330-333.
  152. Peters S, Houwers DJ. 2009. [A cat with diarrhoea associated with the massive presence of Cyniclomyces guttulatus in the faeces]. Tijdschrift Diergeneeskd 134:198-199.
  153. Petit C, Yardley V, Gaboriau F, et al. 1999. Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani. Antimicrob Agents Chemother 43:390-392.
  154. Pinchbeck LR, Hillier A, Kowalski JJ, et al. 2002. Comparison of pulse administration versus once daily administration of itraconazole for the treatment of Malassezia pachydermatis dermatitis and otitis in dogs. J Am Vet Med Assoc 220:1807-1812.
  155. Plotnick AN. 2000. Lipid-based formulations of amphotericin B. J Am Vet Med Assoc 216:838-841.
  156. Plotnick AN, Boshoven EW, Rosychuk RA, et al. 1997. Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog. J Am Anim Hosp Assoc 33:139-143.
  157. Potoski BA, Brown J. 2002. The safety of voriconazole. Clin Infect Dis 35:1273-1275.
  158. 146a. Quimby JM, Hoffman SB, Duke J, et al. 2010. Adverse neurologic events associated with voriconazole use in 3 cats. J Vet Intern Med 24:647-649.
  159. Randall SR, Adams LG, White R, et al. 1996. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution. Am J Vet Res 57:1054-1058.
  160. Rizk MA, Falkler WA, Meiller TF. 2004. Fungal biofilms and drug resistance. Emerg Infect Dis 10:14-19.
  161. Rochette F, Engelen M, Vanden Bossche H. 2003. Antifungal agents of use in animal health—practical applications. J Vet Pharmacol Therap 26:31-53.
  162. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, et al. 1998. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 26:1270-1278.
  163. Roffey SJ, Cole S, Comby P, et al. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731-741.
  164. Rubin SI, Krawiec DR, Gelberg H, et al. 1989. Nephrotoxicity of amphotericin B in dogs, a comparison of two methods of administration. Can J Vet Res 53:23-28.
  165. Schering Corp. 2008. Noxafil. Product information. Schering Corp, Kenilworth, NJ.
  166. Schering-Plough. 2008. Noxafil. Prescribing information. http://www.noxafil.com/prescribinginformation.html. Accessed 7/5/09.
  167. Schering-Plough. 2008. Noxafil. Product insert. Schering-Plough, Kenilworth, NJ.
  168. Scotty NC, Evans TJ, Giuliano E, et al. 2005. In vitro efficacy of lufenuron against filamentous fungi and blood concentrations after PO administration in horses. J Vet Intern Med 19:878-882.
  169. Sharkey PK, Rinaldi MG, Dunn JF, et al. 1991. High dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35:707-713.
  170. Sharp NJH, Harvey CE, O’Brien JA. 1991. Treatment of canine nasal aspergillosis/penicilliosis with fluconazole (UK-49, 858). J Small Anim Pract 32:513-516.
  171. Sharp NJH, Sullivan M. 1989. Use of ketoconazole in the treatment of canine nasal aspergillosis. J Am Vet Med Assoc 194:782-786.
  172. Sharp NJH, Sullivan M, Harvey CE, et al. 1993. Treatment of canine nasal aspergillosis with enilconazole. J Vet Intern Med 7:40-43.
  173. Sheehan DJ, Hitchcock CA, Sibley CM. 1999. Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79.
  174. Shelton GH, Grant CK, Lineberger ML, et al. 1990. Severe neutropenia associated with griseofulvin therapy in cats with feline immunodeficiency virus. J Vet Intern Med 4:317-320.
  175. Shibata K, Nagata M. 2004. Efficacy of griseofulvin for juvenile cellulitis in dogs (abstract FC-20). Vet Dermatol 15(Suppl 1):26.
  176. Siemieniuch MJ, Skarzynski DJ, Kozdrowski R. 2009. Aspergillosis of a dog genital tract—case report. Anim Reprod Sci 112:164-171.
  177. Singh N. 2001. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33:1692-1696.
  178. Smith S, Andrews G, Biller D. 1998. Management of nasal aspergillosis in a dog with a single noninvasive intranasal infusion of clotrimazole. J Am Vet Med Assoc 34:487-492.
  179. Sparkes A, Robinson A, MacKay A, et al. 2000. A study of the efficacy of topical and systemic therapy for the treatment of Microsporum canis infection. J Feline Med Surg 2:135-142.
  180. Sparkes AH. 1996. Terbinafine in cats: a pharmacokinetic study, pp 37-43. In Proceedings of the Third World Congress of Veterinary Dermatology, Edinburgh, Scotland, UK.
  181. Srinivasan J, Ooi WW. 2008. Successful treatment of histoplasmosis brain abscess with voriconazole. Arch Neurol 65:666-667.
  182. Stansfield DG. 1997. A review of the safety and efficacy of lufenuron in dogs and cats. Canine Pract 22:34-38.
  183. Steinbach WJ, Stevens DA. 2003. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37:S157-S187.
  184. Steinbach WJ, Stevens DA, Denning DW. 2003. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2000. Clin Infect Dis 37:S188-S224.
  185. Stevens DA. 1998. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 26:1266-1269.
  186. Sugar AM, Liu XP. 1998. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis 177:1660-1663.
  187. Sugar AM, Liu XP. 2000. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 38:209-212.
  188. Sutton DA, Wickes BL, Thompson EH, et al. 2008. Pulmonary Phialemonium curvatum phaeohyphomycosis in a Standard Poodle dog. Med Mycol 46:355-359.
  189. Szoka FC Jr, Tang M. 1993. Amphotericin B formulated in liposomes and lipid-based systems: a review. J Liposome Res 3:363-375.
  190. Ta M, Flowers SA, Rogers PD. 2009. The role of voriconazole in the treatment of central nervous system blastomycosis. Ann Pharmacother 43:1696-1700.
  191. Taintor J, Crowe C, Hancock S, et al. 2004. Treatment of conidiobolomycosis with fluconazole in two pregnant mares. J Vet Intern Med 18:363-364.
  192. Thompson GR, Cadena J, Patterson TF. 2009. Overview of antifungal agents. Clin Chest Med 30:203-215.
  193. Thornton SJ, Wasan KM. 2009. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv 6:271-284.
  194. Thorpe JE, Baker N, Bromet-Petit M. 1990. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother 34:2032-2033.
  195. Toll J, Ashe CM, Trepanier LA. 2003. Intravesicular administration of clotrimazole for treatment of candiduria in a cat with diabetes mellitus. J Am Vet Med Assoc 223:1156-1158, 1129.
  196. Tomsa K, Glaus TM, Zimmer C, et al. 2003. Fungal rhinitis and sinusitis in three cats. J Am Vet Med Assoc 222:1365, 1380-1384.
  197. Thorpe JE, Baker N, Bromet-Petit M. 1990. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother 34:2032-2033.
  198. Tiches D, Vite C, Dayrell-Har TB, et al. 1998. A case of canine central nervous system cryptococcosis: management with fluconazole. J Am Anim Hosp Assoc 34:145-151.
  199. Vaden SL, Heit MC, Hawkins EC, et al. 1997. Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. J Vet Pharmacol Therap 20:181-186.
  200. Van Oosterhoust ICAM, Venker-van-Haagen AJ. 1991. Aspergillosis: report on diagnosis and treatment. Tijdschr Diergeneeskd 116(Suppl):37-38.
  201. Vlaminck KMJA, Engelen MACM. 2004. Itraconazole: a treatment with pharmacokinetic foundations (abstract supporting original study 12). Vet Dermatol 15(Suppl 1):8.
  202. von Heimendahl A, England GC, Sheldon IM. 2004. Influence of griseofulvin treatment on semen quality in the dog. Anim Reprod Sci 80:174-181.
  203. Wali JP, Aggarwal P, Gupta V, et al. 1992. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar. J Infect Dis 166:215-216.
  204. Wallin LL, Coleman GD, Froeling L, et al. 2001. Rhinosporidiosis in a domestic cat. Med Mycol 39:139-141.
  205. Wang LH, Smith PC, Anderson KL, et al. 1992. High performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies. J Chromatograph 579:259-268.
  206. Ward H. 1994. Itraconazole for the treatment of histoplasmosis in cats. J Vet Intern Med 9:39-42.
  207. Werner AH, Werner BE. 1993. Feline sporotrichosis. Compend Cont Educ Pract Vet 15:1189-1225.
  208. 195a. Westhoff D, Orveillon FX, Farnow D, et al. 2011. Saftey of a non-adjuvantred therapeutic vaccine for the treatment of feline dermatophytosis. Vet Rec 167:899-903.
  209. White MH, Anaissie EJ, Kusne S, et al. 1997. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635-642.
  210. White TC. 1997. Antifungal drug resistance in Candida albicans. ASM News 63:427-433.
  211. White-Weithers N, Medleau L. 1995. Evaluation of topical therapies for the treatment of dermatophyte infected hairs from dogs and cats. J Am Anim Hosp Assoc 31:250-253.
  212. Wiebe V, Karriker M. 2005. Therapy of systemic fungal infections: a pharmacologic perspective. Clin Tech Small Anim Pract 20:250-257.
  213. Wiederhold NP, Tam VH, Chi J, et al. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50:469-473.
  214. Winston DJ, Schiller GJ. 2000. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations. Clin Infect Dis 30:236.
  215. Wray JD, Sparkes AH, Johnson EM. 2008. Infection of the subcutis of the nose in a cat caused by Mucor species: successful treatment using posaconazole. J Feline Med Surg 10:523-527.
  216. Zdovc I, Mičunovi M, Pirš T, et al. 2004. Occurrence of dermatophytes in dogs and cats and their susceptibility to antifungal drugs (abstract P-11). Vet Dermatol 15(Suppl 1):44.
  217. Zhang Ay, Camp WL, Elewski BE. 2007. Advances in topical and systemic antifungals. Dermatol Clin 25:165-183.
  218. Zornes LL, Stratford RE. 1997. Development of a plasma high-performance liquid chromatographic assay for LY303366, a lipopeptide antifungal agent, and its application in a dog pharmacokinetic study. J Chromatograph B 695:381-387.
  219. Zur G, Elad D. 2006. In vitro and in vivo effects of lufenuron on dermatophytes isolated from cases of canine and feline dermatophytoses. J Vet Med B D Infect Dis Vet Public Health 53:122-125.